Healthcare
Live Price
Offline$155.12
+1.31% today
1Y Change
+25.40%
Window
Jun 26, 2025 → Jun 17, 2026
Coverage: 245 bars · Jun 26, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Novartis AG (NVS) is a Healthcare stock with a market cap of $282.81B and listed on NYSE. The stock last traded around $155.12 and up 25.4% across the available one-year price window (Jun 26, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +6.0%, EPS growth of +22.5%, a dividend yield of 3.2%. What stands out right now is revenue +6.0%, EPS +22.5%, free cash flow +28.1% with operating margin 29.9% and ROIC 14.9%. The dividend matters to the case here, with a current yield around 3.2%. Valuation sits in the middle of the pack at P/E 21.0 and price/sales 5.1. Stock Foundry combines NVS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NVS
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NVS Max Drawdown
-15.23%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for NVS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$44.0B
+1.2% YoY
FY Net Income
$24.0B
+245.4% YoY
Free Cash Flow
$12.5B
+4.3% YoY
Revenue Growth
+6.0%
EPS Growth
+22.5%
Gross Margin
75.1%
Net Margin
24.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 54.8B | 51.7B | 46.7B | 43.5B | 44.0B |
| Gross Profit | 41.1B | 38.9B | 34.2B | 31.9B | 32.2B |
| Operating Income | 17.1B | 14.5B | 9.8B | 7.9B | 10.1B |
| EBITDA | 23.0B | 20.7B | 18.3B | 14.7B | 30.9B |
| Net Income | 14.1B | 11.9B | 14.8B | 7.0B | 24.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11.4B | 11.5B | 13.4B | 7.5B | 12.4B |
| Total Assets | 115.6B | 102.2B | 99.9B | 117.5B | 131.8B |
| Total Liabilities | 69.0B | 58.1B | 53.2B | 58.0B | 64.0B |
| Shareholder Equity | 46.1B | 44.0B | 46.7B | 59.3B | 67.7B |
| Total Debt | 37.0B | 31.3B | 26.3B | 27.9B | 31.0B |
| Net Debt | 25.6B | 19.8B | 13.0B | 20.4B | 18.6B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
15.1B
+5.9% YoY
Capital Expenditures
2.6B
-14.2% YoY
Free Cash Flow
12.5B
+4.3% YoY
Key ratios
Gross Margin
75.1%
Operating Margin
29.9%
Net Margin
24.3%
ROE
31.5%
Debt / Equity
1.22x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.